GO:0050654 chondroitin sulfate proteoglycan metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050654 describes the chemical reactions and pathways involving chondroitin sulfate proteoglycans, which are core proteins covalently linked to chondroitin sulfate glycosaminoglycan chains.
• The chondroitin sulfate chain is a repeating disaccharide of beta-(1,4)-D-glucuronic acid and beta-(1,3)-N-acetyl-D-galactosamine, with variable O-sulfation that determines biological function.
• CSPG4 (NG2) is a widely studied chondroitin sulfate proteoglycan and an attractive target for antibody-based immunotherapy and CAR-T/CAR-macrophage approaches in melanoma, glioma, breast and ovarian cancers.
• Sulfation patterns of chondroitin sulfate proteoglycans, such as 4,6 sulfation, regulate nerve regeneration after myocardial infarction, linking this metabolic process to tissue repair.
• Chondroitin sulfate proteoglycans such as neurocan are major components of the brain extracellular matrix and influence neural development and regeneration.
• CRISPR knockout, knock-in, point-mutation and overexpression models enable causal dissection of chondroitin sulfate proteoglycan metabolic genes in cancer, neuroscience and regeneration research.
Description
Chondroitin sulfate proteoglycan metabolic process (GO:0050654) is a biological process that encompasses the chemical reactions and pathways involving chondroitin sulfate proteoglycans (CSPGs), which consist of a core protein linked to a chondroitin sulfate glycosaminoglycan. These molecules are abundant in the extracellular matrix and on cell surfaces, where they participate in cell adhesion, signaling, and tissue organization. The chondroitin sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, the latter of which can be O-sulfated, generating structural diversity that underlies functional specificity. Researchers study GO:0050654 because CSPGs are implicated in a wide range of physiological and pathological contexts, including nervous system development, nerve regeneration after injury, and cancer progression. For example, chondroitin sulfate proteoglycan 4 (CSPG4), also known as NG2, is a cell-surface CSPG that has emerged as an attractive target for antibody-based immunotherapy and for CAR-T and CAR-macrophage cell therapies in melanoma, glioma, triple-negative breast cancer and ovarian cancer. In the brain, CSPGs such as neurocan are key constituents of the extracellular matrix and influence neural plasticity and regeneration. Understanding the metabolic process of chondroitin sulfate proteoglycans therefore requires integrating knowledge of core protein synthesis, glycosaminoglycan chain assembly, sulfation, and trafficking. This article summarizes the authoritative GO definition, the major genes and proteins involved, disease links, and the experimental methods, including CRISPR-based models, used to investigate this process.
chondroitin sulfate proteoglycan metabolic process At A Glance
| GO ID | GO:0050654 |
|---|---|
| GO term | chondroitin sulfate proteoglycan metabolic process |
| Ontology | biological_process |
| Synonym | chondroitin sulfate proteoglycan metabolism; chondroitin sulphate proteoglycan metabolic process; chondroitin sulphate proteoglycan metabolism |
| Major function | Chemical reactions and pathways involving chondroitin sulfate proteoglycans, including core protein synthesis, glycosaminoglycan chain assembly and sulfation |
| Representative core protein | CSPG4 (NG2), a chondroitin sulfate proteoglycan studied in cancer and neural biology |
| Chain composition | Repeating disaccharide beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine with O-sulfation |
| Disease relevance | Cancer immunotherapy targets, glioma, melanoma, breast and ovarian cancer, nerve regeneration |
| Research methods | CRISPR knockout/knock-in, CAR-T and CAR-macrophage models, sulfation analysis, imaging |
What Is GO:0050654?
GO:0050654 (chondroitin sulfate proteoglycan metabolic process) is defined as the chemical reactions and pathways involving chondroitin sulfate proteoglycans, which consist of a core protein linked to a chondroitin sulfate glycosaminoglycan. The chondroitin sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, the latter of which can be O-sulfated. In simpler terms, it covers all the steps by which cells build, modify, transport and break down chondroitin sulfate proteoglycans, including the synthesis of the core protein, attachment and polymerization of the chondroitin sulfate chain, sulfation, and subsequent trafficking or turnover.
Why Is chondroitin sulfate proteoglycan metabolic process Important in Cell Biology?
GO:0050654 is important because chondroitin sulfate proteoglycans are not merely structural matrix molecules; they are dynamic regulators of cell signaling, adhesion and tissue repair, and their metabolic processing determines the sulfation patterns that dictate biological activity. Dysregulation of CSPG metabolism contributes to cancer progression and to the failure of nerve regeneration after injury, making this process a focal point for therapeutic development. The emergence of CSPG4 as a target for antibody-based immunotherapy and for CAR-T and CAR-macrophage therapies in melanoma, glioma, breast and ovarian cancer underscores the translational significance of understanding how these proteoglycans are synthesized, modified and presented on the cell surface.
• CSPG4 is an attractive target for antibody-based immunotherapy across multiple cancers.
• CSPG4 and B7-H3 co-targeting enables Pan-CAR-T cell treatment of triple-negative breast cancer.
• Human CSPG4-targeting CAR-macrophages inhibit melanoma growth.
• CSPG4 provides a new treatment approach to preventing peritoneal dissemination in ovarian cancer.
• CSPG4 significance in human gliomas highlights its role in brain tumor biology.
• Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction.
• Neurocan, a brain chondroitin sulfate proteoglycan, is a key extracellular matrix component in the nervous system.
• Chondroitin sulfate accelerates trans-Golgi-to-surface transport of proteoglycan amyloid precursor protein, linking CSPG metabolism to protein trafficking.
What Happens During chondroitin sulfate proteoglycan metabolic process?
Core protein synthesis and initial glycosylation
In simple terms: The cell first makes the protein backbone of the proteoglycan and attaches the first sugar link.
The metabolic process begins with synthesis of the core protein of the chondroitin sulfate proteoglycan, such as CSPG4 (NG2) or neurocan, in the endoplasmic reticulum and its transit through the secretory pathway. The core protein is then modified by the addition of a linker tetrasaccharide that serves as the attachment point for the chondroitin sulfate chain. This step is a prerequisite for the subsequent polymerization of the glycosaminoglycan chain and is part of the broader GO:0050654 process.
Chondroitin sulfate chain polymerization
In simple terms: Enzymes build the long sugar chain by repeatedly adding two-sugar units.
The chondroitin sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine. Polymerization of this chain occurs through the alternating addition of glucuronic acid and N-acetyl-D-galactosamine residues, generating the characteristic glycosaminoglycan structure. The length and number of chains influence the physical and signaling properties of the proteoglycan.
O-sulfation of the chondroitin sulfate chain
In simple terms: The sugar chain gets decorated with sulfate groups at specific positions, which changes its function.
The N-acetyl-D-galactosamine residues of the chondroitin sulfate chain can be O-sulfated, producing diverse sulfation patterns. Chondroitin sulfate proteoglycan 4,6 sulfation has been shown to regulate sympathetic nerve regeneration after myocardial infarction, demonstrating that specific sulfation motifs carry functional information. Sulfation therefore represents a key regulatory step within GO:0050654 that determines interactions with growth factors, receptors and extracellular matrix components.
Trafficking and cell-surface presentation
In simple terms: After being built, the proteoglycan is transported to the cell surface or secreted.
Following synthesis and modification, chondroitin sulfate proteoglycans are transported through the Golgi apparatus to the cell surface or secreted into the extracellular matrix. Chondroitin sulfate has been shown to accelerate trans-Golgi-to-surface transport of proteoglycan amyloid precursor protein, indicating that glycosaminoglycan chains can influence trafficking kinetics. Cell-surface presentation of CSPG4 is critical for its recognition by therapeutic antibodies and CAR constructs.
Turnover and extracellular matrix remodeling
In simple terms: Old or excess proteoglycans are broken down and their components recycled or released.
The metabolic process also encompasses turnover of chondroitin sulfate proteoglycans, including proteolytic cleavage of core proteins and degradation of glycosaminoglycan chains. In the brain, CSPGs such as neurocan are components of the extracellular matrix whose remodeling affects neural plasticity and regeneration. In pathological contexts, altered turnover and sulfation of CSPGs contribute to tumor microenvironment remodeling and to barriers against nerve regeneration.
Key Genes Involved in GO:0050654 chondroitin sulfate proteoglycan metabolic process
The following genes and proteins are central to chondroitin sulfate proteoglycan metabolic process (GO:0050654) and are frequently studied in cancer, neuroscience and regeneration research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CSPG4 (NG2) | Chondroitin sulfate proteoglycan 4 core protein; cell-surface proteoglycan | Target for antibody-based immunotherapy and CAR-T/CAR-macrophage therapy in melanoma, glioma, breast and ovarian cancer |
| B7-H3 (CD276) | Immune checkpoint molecule co-targeted with CSPG4 | Pan-CAR-T cell treatment of triple-negative breast cancer |
| NCAN (neurocan) | Brain chondroitin sulfate proteoglycan | Neural development, extracellular matrix and regeneration |
| APP | Amyloid precursor protein, a proteoglycan carrier | Chondroitin sulfate accelerates trans-Golgi-to-surface transport of proteoglycan APP |
| CHST family sulfotransferases | O-sulfation of chondroitin sulfate chains | Determines 4,6 sulfation patterns that regulate nerve regeneration |
| CHPF/CHPF2 | Chondroitin sulfate polymerization enzymes | Chain elongation of chondroitin sulfate glycosaminoglycan |
| CHSY1/CHSY3 | Chondroitin sulfate synthase enzymes | Biosynthesis of the repeating disaccharide unit |
| CSGALNACT1/2 | Chondroitin sulfate N-acetylgalactosaminyltransferases | Initiation and elongation of chondroitin sulfate chains |
| UST | Uronyl 2-sulfotransferase | Sulfation of chondroitin sulfate and related glycosaminoglycans |
| SULF1/SULF2 | Extracellular sulfatases | Modulate sulfation and signaling of proteoglycans |
| ACAN | Aggrecan core protein | Major chondroitin sulfate proteoglycan in cartilage and matrix |
| VCAN | Versican core protein | Chondroitin sulfate proteoglycan in extracellular matrix |
| BCAN | Brevican core protein | Brain-specific chondroitin sulfate proteoglycan |
| DCN | Decorin core protein | Small chondroitin/dermatan sulfate proteoglycan |
| GPC1-6 | Glypican family heparan sulfate proteoglycans | Related proteoglycan biology and trafficking |
| SDC1-4 | Syndecan family proteoglycans | Cell-surface proteoglycan signaling |
| HSPG2 | Perlecan core protein | Basement membrane proteoglycan |
| PTPRZ1 | Phosphacan, a chondroitin sulfate proteoglycan | Neural extracellular matrix and signaling |
How Is chondroitin sulfate proteoglycan metabolic process Regulated?
The chondroitin sulfate proteoglycan metabolic process is regulated at multiple levels, including transcription of core protein genes, activity of glycosyltransferases and sulfotransferases, and post-translational trafficking. Sulfation patterns, such as chondroitin sulfate proteoglycan 4,6 sulfation, are dynamically regulated and influence sympathetic nerve regeneration after myocardial infarction. Chondroitin sulfate itself can accelerate trans-Golgi-to-surface transport of proteoglycan amyloid precursor protein, indicating that glycosaminoglycan availability regulates trafficking. In cancer, CSPG4 expression and surface presentation are modulated in ways that affect recognition by therapeutic antibodies and CAR constructs. These regulatory layers collectively determine the functional output of GO:0050654 in different tissues.
chondroitin sulfate proteoglycan metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CSPG4 | Melanoma growth and immunotherapy | CSPG4-targeting CAR-macrophage in melanoma models |
| CSPG4 | Triple-negative breast cancer | CSPG4 and B7-H3 co-targeting Pan-CAR-T cells |
| CSPG4 | Ovarian cancer peritoneal dissemination | CSPG4-targeted treatment in ovarian cancer models |
| CSPG4 | Human gliomas | CSPG4 expression and targeting studies in glioma |
| CSPG4 sulfation | Sympathetic nerve regeneration after myocardial infarction | Chondroitin sulfate 4,6 sulfation manipulation in regeneration models |
Chondroitin sulfate proteoglycan metabolic process in cancer
CSPG4 is overexpressed in several malignancies and has emerged as an attractive target for antibody-based immunotherapy. In human gliomas, CSPG4 significance has been documented, supporting its role in brain tumor biology. CSPG4 and B7-H3 co-targeting enables Pan-CAR-T cell treatment of triple-negative breast cancer, demonstrating the therapeutic potential of targeting this proteoglycan. Human CSPG4-targeting CAR-macrophages inhibit melanoma growth, further validating CSPG4 as an immunotherapy target. In ovarian cancer, CSPG4 provides a new treatment approach to preventing peritoneal dissemination.
Chondroitin sulfate proteoglycan metabolic process in neural regeneration
Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction, linking specific sulfation patterns to regenerative outcomes. Neurocan, a brain chondroitin sulfate proteoglycan, is a major extracellular matrix component that influences neural development and regeneration. These findings indicate that the metabolic processing and sulfation of CSPGs are critical determinants of whether nerves regenerate after injury.
Chondroitin sulfate proteoglycan metabolic process and protein trafficking
Chondroitin sulfate accelerates trans-Golgi-to-surface transport of proteoglycan amyloid precursor protein, connecting CSPG metabolism to intracellular trafficking pathways relevant to neurodegeneration. This observation suggests that perturbations in chondroitin sulfate synthesis or sulfation could influence the localization and processing of amyloid precursor protein.
From chondroitin sulfate proteoglycan metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CSPG4 affect tumor growth? | CSPG4 knockout cancer cell lines and xenograft models |
| Does a specific sulfation motif regulate nerve regeneration? | Point-mutation or knock-in of sulfotransferase genes in regeneration models |
| Can CSPG4 be targeted by CAR-T cells? | Knock-in of CAR constructs and co-culture with CSPG4-positive tumor cells |
| How does chondroitin sulfate affect APP trafficking? | Overexpression or knockout of chondroitin sulfate enzymes in trafficking assays |
| What is the role of neurocan in brain extracellular matrix? | Neurocan knockout or overexpression in neural culture systems |
| Can CSPG4-targeting CAR-macrophages inhibit melanoma? | CSPG4-targeting CAR-macrophage in melanoma models |
How to Study the chondroitin sulfate proteoglycan metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene requirement for CSPG metabolism | Identify regulators of CSPG4 surface expression |
| Sulfation analysis | Chondroitin sulfate sulfation patterns | Link 4,6 sulfation to nerve regeneration |
| Live-cell imaging | Trans-Golgi-to-surface trafficking | Study chondroitin sulfate effect on APP transport |
| CAR-T co-culture | Tumor cell killing by engineered T cells | Target CSPG4 and B7-H3 in breast cancer |
| CAR-macrophage assay | Phagocytosis and tumor inhibition | Target CSPG4 in melanoma |
| Immunohistochemistry | CSPG4 expression in tissues | Assess glioma and ovarian cancer samples |
| Glycosaminoglycan chromatography | Chain length and disaccharide composition | Characterize chondroitin sulfate polymers |
| Knock-in reporter models | Localization of tagged core proteins | Track proteoglycan trafficking and turnover |
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify genes required for chondroitin sulfate proteoglycan metabolic process, including core protein genes and glycosyltransferases. Such screens are particularly useful for discovering regulators of CSPG4 surface presentation that affect CAR-T or antibody recognition.
Sulfation and glycosaminoglycan analysis
Biochemical analysis of chondroitin sulfate chain composition and sulfation patterns is essential for studying GO:0050654. Chondroitin sulfate proteoglycan 4,6 sulfation has been linked to sympathetic nerve regeneration, illustrating how sulfation analysis can reveal functional motifs.
Imaging and trafficking assays
Live-cell imaging and trafficking assays can monitor the trans-Golgi-to-surface transport of proteoglycans such as amyloid precursor protein, which is accelerated by chondroitin sulfate. These methods help dissect the secretory pathway steps of the metabolic process.
Immunotherapy and co-culture models
CAR-T and CAR-macrophage co-culture assays with CSPG4-positive tumor cells provide functional readouts for therapeutic targeting of chondroitin sulfate proteoglycans. These models integrate the metabolic process with immune recognition and killing.
How CRISPR Can Be Used to Study GO:0050654 chondroitin sulfate proteoglycan metabolic process
Knockout
CRISPR knockout of CSPG4 or of chondroitin sulfate biosynthetic enzymes allows researchers to test the requirement for chondroitin sulfate proteoglycan metabolic process in tumor growth, immune recognition and neural regeneration. For example, knocking out CSPG4 in melanoma or glioma cells can reveal its contribution to proliferation and to sensitivity to CAR-macrophage or antibody therapies.
Point Mutation
Point mutations can be introduced into sulfotransferase genes or into specific residues of core proteins to dissect the role of sulfation motifs such as chondroitin sulfate 4,6 sulfation in nerve regeneration. Such models help distinguish the function of individual sulfation sites from overall proteoglycan abundance.
Knock-in
Knock-in of epitope tags or fluorescent reporters into endogenous CSPG4 or neurocan loci enables tracking of proteoglycan trafficking and localization without overexpression artifacts. Knock-in of CAR constructs into T cells or macrophages is also used to generate CSPG4-targeting therapeutic cells.
Overexpression
Overexpression of CSPG4 or of chondroitin sulfate biosynthetic enzymes can model the elevated proteoglycan levels seen in tumors and in extracellular matrix remodeling. Overexpression of chondroitin sulfate enzymes has been used to study accelerated trans-Golgi-to-surface transport of amyloid precursor protein.
How EDITGENE Supports chondroitin sulfate proteoglycan metabolic process Research
Researchers studying chondroitin sulfate proteoglycan metabolic process-related genes often need to determine whether a candidate gene is causally involved in core protein synthesis, glycosaminoglycan chain assembly, sulfation, trafficking or turnover. EDITGENE provides CRISPR-based cell model services that enable such causal experiments in relevant cancer, neural and stromal cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for chondroitin sulfate proteoglycan metabolic process research.
Frequently Asked Questions About chondroitin sulfate proteoglycan metabolic process
What is GO:0050654 chondroitin sulfate proteoglycan metabolic process?
GO:0050654 is a biological process describing the chemical reactions and pathways involving chondroitin sulfate proteoglycans, which consist of a core protein linked to a chondroitin sulfate glycosaminoglycan.
What genes are involved in chondroitin sulfate proteoglycan metabolic process?
Key genes include CSPG4 (NG2), NCAN (neurocan), ACAN, VCAN, BCAN, and chondroitin sulfate biosynthetic enzymes such as CHSY1, CHPF and sulfotransferases.
What is the structure of the chondroitin sulfate chain?
The chain is composed of the repeating disaccharide unit beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, the latter of which can be O-sulfated.
Why is CSPG4 important in cancer?
CSPG4 is an attractive target for antibody-based immunotherapy and for CAR-T and CAR-macrophage therapies in melanoma, glioma, breast and ovarian cancer.
How does chondroitin sulfate sulfation affect nerve regeneration?
Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction, showing that specific sulfation patterns are functionally important.
What is neurocan and how does it relate to GO:0050654?
Neurocan is a brain chondroitin sulfate proteoglycan and a major extracellular matrix component whose synthesis and modification are part of GO:0050654.
Can CRISPR be used to study chondroitin sulfate proteoglycan metabolic process?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are used to dissect the roles of CSPG4 and biosynthetic enzymes in this process.
What diseases are linked to chondroitin sulfate proteoglycan metabolic process?
It is linked to melanoma, glioma, triple-negative breast cancer, ovarian cancer and impaired nerve regeneration after myocardial infarction.
How does chondroitin sulfate affect amyloid precursor protein trafficking?
Chondroitin sulfate accelerates trans-Golgi-to-surface transport of proteoglycan amyloid precursor protein, linking CSPG metabolism to trafficking.
What experimental models are used to study GO:0050654?
Models include CSPG4 knockout cancer cells, CAR-T and CAR-macrophage co-cultures, sulfation analysis, live-cell imaging and knock-in reporter lines.
Conclusion
GO:0050654 chondroitin sulfate proteoglycan metabolic process encompasses the synthesis, sulfation, trafficking and turnover of chondroitin sulfate proteoglycans, molecules that are central to extracellular matrix biology, neural regeneration and cancer. The emergence of CSPG4 as a target for antibody-based immunotherapy and CAR-T/CAR-macrophage therapies highlights the translational importance of understanding this process. Continued research using CRISPR models and biochemical analysis of sulfation will further clarify how chondroitin sulfate proteoglycan metabolism can be harnessed for therapeutic benefit.
References
- 1. Stucchi S et al.. 2025. B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer.. J Immunother Cancer 13(5) PMID: 40425233
- 2. Kurokawa T et al.. 2024. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.. Proc Jpn Acad Ser B Phys Biol Sci 100(5):293-308 PMID: 38735753
- 3. Blake MR et al.. 2022. Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction.. Elife 11 PMID: 35604022
- 4. Greiner D et al.. 2025. Human CSPG4-targeting CAR-macrophages inhibit melanoma growth.. Oncogene 44(22):1665-1677 PMID: 40082557
- 5. Rauch U et al.. 2001. Neurocan: a brain chondroitin sulfate proteoglycan.. Cell Mol Life Sci 58(12-13):1842-56 PMID: 11766883
- 6. Schiffer D et al.. 2018. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.. Int J Mol Sci 19(9) PMID: 30213051
- 7. Mihov D et al.. 2015. Chondroitin Sulfate Accelerates Trans-Golgi-to-Surface Transport of Proteoglycan Amyloid Precursor Protein.. Traffic 16(8):853-70 PMID: 25951880
- 8. Uno K et al.. 2024. Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in Ovarian Cancer.. Int J Mol Sci 25(3) PMID: 38338902
